0 9 NF-kappaB NF-kappaB NNP 10 14 only only RB 15 24 partially partially RB 25 33 mediates mediate VBZ 34 46 Epstein-Barr epstein-barr JJ 47 52 virus virus NN 53 59 latent latent JJ 60 68 membrane membrane NN 69 76 protein protein NN 77 78 1 1 CD 79 89 activation activation NN 90 92 of of IN 93 94 B B NNP 95 100 cells cell NNS 100 101 . . . 103 106 The the DT 107 113 latent latent JJ 114 122 membrane membrane NN 123 130 protein protein NN 131 132 1 1 CD 133 134 ( ( ( 134 138 LMP1 lmp1 NN 138 139 ) ) ) 140 142 of of IN 143 155 Epstein-Barr epstein-barr JJ 156 161 virus virus NN 162 163 ( ( ( 163 166 EBV EBV NNP 166 167 ) ) ) 168 170 is be VBZ 171 179 required require VBN 180 183 for for IN 184 195 EBV-induced ebv-induced JJ 196 211 immortalization immortalization NN 212 214 of of IN 215 220 human human JJ 221 222 B B NNP 223 228 cells cell NNS 229 232 and and CC 233 239 causes cause VBZ 240 251 tumorigenic tumorigenic JJ 252 266 transformation transformation NN 267 269 of of IN 270 274 cell cell NN 275 280 lines line NNS 280 281 . . . 282 286 LMP1 lmp1 NN 287 297 expression expression NN 298 305 induces induce VBZ 306 316 phenotypic phenotypic JJ 317 324 changes change NNS 325 335 resembling resemble VBG 336 337 B B NNP 338 342 cell cell NN 343 353 activation activation NN 353 354 , , , 355 359 such such JJ 360 362 as as IN 363 367 cell cell NN 368 372 size size NN 373 381 increase increase NN 382 385 and and CC 386 399 up-regulation up-regulation NN 400 402 of of IN 403 407 cell cell NN 408 415 surface surface NN 416 426 activation activation NN 427 434 markers marker NNS 434 435 . . . 436 440 LMP1 LMP1 NNP 441 449 contains contain VBZ 450 453 two two CD 454 461 domains domain NNS 462 466 that that WDT 467 475 activate activate VBP 476 479 the the DT 480 493 transcription transcription NN 494 500 factor factor NN 501 510 NF-kappaB NF-kappaB NNP 510 511 , , , 512 515 one one CD 516 523 through through IN 524 536 interactions interaction NNS 537 541 with with IN 542 546 TRAF TRAF NNP 547 555 proteins protein NNS 556 559 and and CC 560 563 the the DT 564 569 other other JJ 570 574 with with IN 575 578 the the DT 579 584 TRADD TRADD NNP 585 592 protein protein NN 592 593 . . . 594 597 The the DT 598 605 purpose purpose NN 606 608 of of IN 609 612 the the DT 613 620 present present JJ 621 626 study study NN 627 630 was be VBD 631 633 to to TO 634 645 investigate investigate VB 646 649 the the DT 650 660 importance importance NN 661 663 of of IN 664 673 NF-kappaB NF-kappaB NNP 674 683 induction induction NN 684 686 in in IN 687 690 the the DT 691 704 up-regulation up-regulation NN 705 707 of of IN 708 711 the the DT 712 713 B B NNP 714 718 cell cell NN 719 729 activation activation NN 730 737 markers marker NNS 738 744 ICAM-1 icam-1 NN 745 748 and and CC 749 753 CD71 CD71 NNP 754 756 by by IN 757 761 LMP1 LMP1 NNP 761 762 . . . 763 767 This this DT 768 773 study study NN 774 779 shows show VBZ 780 784 that that IN 785 795 expression expression NN 796 798 of of IN 799 803 LMP1 LMP1 NNP 804 813 activates activate VBZ 814 827 transcription transcription NN 828 832 from from IN 833 841 p50/p65- p50/p65- NN 842 845 and and CC 846 852 c-Rel- c-rel- NN 853 863 responsive responsive JJ 864 873 promoters promoter NNS 873 874 , , , 875 878 and and CC 879 883 that that IN 884 888 this this DT 889 897 activity activity NN 898 901 can can MD 902 904 be be VB 905 915 completely completely RB 916 925 inhibited inhibit VBN 926 928 by by IN 929 939 expression expression NN 940 942 of of IN 943 944 a a DT 945 953 dominant dominant JJ 954 964 inhibitory inhibitory JJ 965 972 IkappaB ikappab NN 973 979 mutant mutant NN 979 980 . . . 981 987 ICAM-1 ICAM-1 NNP 988 991 and and CC 992 996 CD71 CD71 NNP 997 1000 are be VBP 1001 1013 nevertheless nevertheless RB 1014 1026 up-regulated up-regulate VBN 1027 1029 by by IN 1030 1034 LMP1 lmp1 NN 1035 1037 in in IN 1038 1045 primary primary JJ 1046 1047 B B NNP 1048 1053 cells cell NNS 1054 1057 and and CC 1058 1062 cell cell NN 1063 1068 lines line NNS 1069 1079 expressing express VBG 1080 1083 the the DT 1084 1092 dominant dominant JJ 1093 1100 IkappaB ikappab NN 1100 1101 . . . 1102 1113 Furthermore furthermore RB 1113 1114 , , , 1115 1127 LMP1-induced lmp1-induced JJ 1128 1132 cell cell NN 1133 1137 size size NN 1138 1146 increase increase NN 1147 1149 of of IN 1150 1157 primary primary JJ 1158 1159 B B NNP 1160 1165 cells cell NNS 1166 1169 was be VBD 1170 1180 unaffected unaffected JJ 1181 1183 by by IN 1184 1191 IkappaB IkappaB NNP 1192 1202 expression expression NN 1202 1203 . . . 1204 1206 It it PRP 1207 1210 was be VBD 1211 1220 concluded conclude VBN 1221 1225 that that IN 1226 1230 even even RB 1231 1235 when when WRB 1236 1240 LMP1 lmp1 NN 1241 1243 is be VBZ 1244 1250 unable unable JJ 1251 1253 to to TO 1254 1262 activate activate VB 1263 1272 NF-kappaB NF-kappaB NNP 1272 1273 , , , 1274 1276 it it PRP 1277 1279 is be VBZ 1280 1285 still still RB 1286 1293 capable capable JJ 1294 1296 of of IN 1297 1305 inducing induce VBG 1306 1313 certain certain JJ 1314 1329 characteristics characteristic NNS 1330 1332 of of IN 1333 1342 activated activate VBN 1343 1344 B b NN 1345 1350 cells cell NNS 1350 1351 , , , 1352 1360 strongly strongly RB 1361 1371 suggesting suggest VBG 1372 1376 that that IN 1377 1381 LMP1 lmp1 NN 1382 1385 can can MD 1386 1390 also also RB 1391 1399 activate activate VB 1400 1405 cells cell NNS 1406 1419 independently independently RB 1420 1422 of of IN 1423 1432 NF-kappaB NF-kappaB NNP 1432 1433 . . .